Estudo retrospectivo de 124 casos de tumores de glândulas salivares em uma população brasileira

Salivary gland tumors constitute a highly heterogeneous histopathologic group. There are few epidemiological studies of large series of benign and malignant salivary gland tumors in Brazil. MATERIAL AND METHODS: Hospital records of 124 patients with salivary gland tumors diagnosed from January 1993 to December 1999 were reviewed. The patients were analyzed according to gender, age, size, location, and histopathology of the tumor. RESULTS AND CONCLUSIONS: Patients with benign and malignant tumors presented with a mean age of 47.7 and 48.8 years, respectively. The frequency of benign tumors was 80% (n = 99) and malignant tumors 20% (n = 25). Tumors were localized in the parotid gland 71% (n = 88), in the submandibular gland 24% (n = 30), and in the minor salivary glands 5% (n = 6). The most common benign tumors were pleomorphic adenoma in 84% (n = 84) and Warthin's tumor in 13% (n = 13). Among malignant tumors, mucoepidermoid carcinoma was the most common in 52% (n = 13), adenoid cystic carcinoma occurred in 20% (n = 5), and carcinoma ex pleomorphic adenoma was detected in 12% (n = 3).Tumores de glândulas salivares apresentam características histopatológicas altamente heterogêneas. Existem poucos estudos epidemiológicos analisando um número elevado de tumores de glândulas salivares benignos e malignos no Brasil. MATERIAL E MÉTODOS: Revisamos os prontuários hospitalares de 124 pacientes com tumores de glândulas salivares durante o período de Janeiro de 1993 até Dezembro de 1999. Os pacientes foram analisados de acordo com o sexo, idade, tamanho do tumor, localização e tipo histopatológico. RESULTADOS E CONCLUSÕES: Pacientes com tumores benignos e malignos apresentaram uma média de idade de 47,7 e 48,8 anos, respectivamente. A freqüência de ocorrência dos tumores benignos foi de 80% (n=99) e dos tumores malignos de 20% (n=25). Tumores foram localizados na parótida em 71% (n=88) dos casos, na glândula submandibular em 24% (n=30), e glândulas salivares menores em 5% (n=6). Os principais tumores benignos foram o Adenoma Pleomórfico que representou 84% (n=84) dos casos e o Tumor de Warthin com 13% (n=13) dos casos. Entre os tumores malignos, o Carcinoma Mucoepidermóide foi o mais comum correspondendo a 52% dos casos (n=13), seguido pelo Carcinoma Adenóide Cístico em 20% (n=5) e Carcinoma ex Adenoma Pleomórfico que foi detectado em 12% dos casos (n=3)

NDRG1 protein overexpression in malignant thyroid neoplasms

OBJECTIVES: The aim of this study was to examine the expression of the N-myc downstream-regulated gene 1 protein in benign and malignant lesions of the thyroid gland by immunohistochemistry. INTRODUCTION: N-myc downstream-regulated gene 1 encodes a protein whose expression is induced by various stimuli, including cell differentiation, exposure to heavy metals, hypoxia, and DNA damage. Increased N-myc downstream-regulated gene 1 expression has been detected in various types of tumors, but the role of N-myc downstream-regulated gene 1 expression in thyroid lesions remains to be determined. METHODS: A tissue microarray paraffin block containing 265 tissue fragments corresponding to normal thyroid, nodular goiter, follicular adenoma, papillary thyroid carcinoma (classical pattern and follicular variant), follicular carcinoma, and metastases of papillary and follicular thyroid carcinomas were analyzed by immunohistochemistry using a polyclonal anti- N-myc downstream-regulated gene 1 antibody. RESULTS: The immunohistochemical expression of N-myc downstream-regulated gene 1 was higher in carcinomas compared to normal thyroid glands and nodular goiters, with higher expression in classical papillary thyroid carcinomas and metastases of thyroid carcinomas (P < 0.001). A combined analysis showed higher immunohistochemical expression of NDRG1 in malignant lesions (classical pattern and follicular variant of papillary thyroid carcinomas, follicular carcinomas, and metastases of thyroid carcinomas) compared to benign thyroid lesions (goiter and follicular adenomas) (P = 0.043). In thyroid carcinomas, N-myc downstream-regulated gene 1 expression was significantly correlated with a more advanced TNM stage (P = 0.007) and age, metastasis, tumor extent, and size (AMES) high-risk group (P = 0.012). CONCLUSIONS: Thyroid carcinomas showed increased immunohistochemical N-myc downstream-regulated gene 1 expression compared to normal and benign thyroid lesions and is correlated with more advanced tumor stages

Study of the diagnostic and prognostic role of immunohistochemical expression of NDRG1, osteonectin, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1 and galectin-3 in thyroid specimens by tissue microarray

INTRODUÇÃO: O crescimento e a progressão de diversos tipos de tumores dependem da angiogênese, isto é, a formação de novos vasos sanguíneos. Fatores da família do VEGF (VEGF-A, VEGF-C, Flk-1/KDR) são potentes mediadores da angiogênese e níveis elevados destes fatores podem ser detectados em vários tumores humanos. Outras proteínas como NDRG1, osteonectina, HIF-1 e galectina-3 encontram-se associadas, de modo indireto, à angiogênese. MÉTODOS: O objetivo deste estudo foi analisar a expressão imunoistoquímica de NDRG1, osteonectina, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1 e galectina-3 em 265 lesões benignas e malignas da tireóide por tissue microarray (TMA), incluindo tireóide normal, bócio, adenoma folicular, carcinoma papilífero, carcinoma folicular e metástases de carcinoma papilífero e folicular da tireóide. Lâminas em diferentes níveis do bloco de TMA foram submetidas à reação imunoistoquímica utilizando-se anticorpos específicos contra NDRG1, osteonectina, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1, galectina-3. Foi realizada uma avaliação semiquantitativa da expressão destas proteínas, analisando-se a intensidade de coloração e a porcentagem de células positivas para cada marcador. RESULTADOS: De um modo geral, a expressão de NDRG1, osteonectina, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1 e galectina-3 foi maior nos carcinomas de tireóide em relação ao bócio e adenoma folicular. Dentre as proteínas estudadas, a galectina-3 foi aquela que apresentou melhor acurácia diagnóstica na distinção entre lesões benignas e malignas da tireóide, com uma sensibilidade 64,1% e especificidade de 94,4%. Nos carcinomas de tireóide, a expressão de NDRG1, VEGF-A, VEGF-C e HIF-1 apresentou correlação estatística significativa com estádio TNM mais avançado e alto risco pelo método AMES. A análise multivariada revelou que a idade 45 anos, o tamanho tumoral maior do que 4,0 cm, o estádio IV do TNM e a perda de expressão de galectina-3 foram fatores que contribuíram para a recorrência ou óbito em pacientes com carcinoma de tireóide. CONCLUSÕES: Nos carcinomas de tireóide, a expressão de NDRG1, VEGF-A, VEGF-C, HIF-1 se correlacionou com tumores mais avançados. Com exceção da galectina-3, nenhuma das proteínas estudadas apresentou impacto na sobrevida dos pacientes com carcinoma de tireóide. Nestes pacientes, a perda de expressão de galectina-3 foi um fator de risco para recorrência ou óbito.INTRODUCTION: The growth and progression of different types of tumors depend on angiogenesis, i.e., the formation of new blood vessels. Members of the VEGF family (VEGF-A, VEGF-C, Flk-1/KDR) are potent mediators of angiogenesis and elevated levels of these factors can be detected in various human tumors. Other proteins such as NDRG1, osteonectin, HIF-1 and galectin-3 are indirectly associated with angiogenesis. METHODS: The objective of this study was to investigate the immunohistochemical expression of NDRG1, osteonectin, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1 and galectin-3 in 265 benign and malignant thyroid lesions by tissue microarray (TMA), including normal thyroid, goiter, follicular adenoma, papillary carcinoma, follicular carcinoma, and papillary and follicular thyroid carcinoma metastases. Slides obtained from different levels of the TMA block were submitted to immunohistochemistry using specific antibodies against NDRG1, osteonectin, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1, and galectin-3. The expression of these proteins was analyzed semiquantitatively, evaluating the intensity of staining and the percentage of positive cells for each marker. RESULTS: In general, the expression of NDRG1, osteonectin, VEGF-A, VEGF-C, Flk-1/KDR, HIF-1 and galectin-3 was higher in thyroid carcinomas when compared to goiter and follicular adenoma. Among the proteins studied, galectin-3 presented the best diagnostic accuracy in the distinction between benign and malignant thyroid lesions, with a sensitivity of 64.1% and specificity of 94.4%. In thyroid carcinomas, the expression of NDRG1, VEGF-A, VEGF-C and HIF-1 was significantly correlated with a more advanced TNM stage and AMES high risk. Multivariate analysis revealed that age 45 years, tumor size > 4.0 cm, TNM stage IV and loss of expression of galectin-3 were associated with recurrence or death in patients with thyroid carcinoma. CONCLUSIONS: In thyroid carcinomas, the expression of NDRG1, VEGF-A, VEGF-C and HIF-1 is correlated with more advanced tumors. Except for galectin-3, none of the proteins studied had an impact on the survival of patients with thyroid carcinoma. In these patients, loss of expression of galectin-3 was a risk factor for recurrence or death

Claudin expression in breast cancer: High or low, what to expect?

. The evaluation of claudins (CLDNs) expression pattern in tumours can be important to understand breast carcinogenesis. The study of CLDNs became more appealing since it was found that CLDN3 and CLDN4 are putative therapeutic targets for Clostridium perfrigens enterotoxin (CPE), as well as for monoclonal antibody-based therapy. Moreover, the recently characterized CLDN-low molecular subgroup of breast tumours increased the interest in these molecules. Based on these facts, our aim was to explore the pattern of expression of CLDNs among a large series of invasive breast carcinomas. We also analysed the correlation between the combinatorial expression of CLDN3/CLDN4 and classical prognostic factors and biological markers. In addition, we also compared the characteristics of tumours with low expression of CLDN3, CLDN4 and CLDN7, assessed by immunohistochemistry (IHC), and the ones from CLDN-low subgroup of tumours previously defined by genomic assays. The combinatorial analysis of the expression of CLDN3/CLDN4 showed a significant association between high CLDN3/CLDN4 levels and triple-negative tumours, as well as with worse patient outcome. This combined analysis may provide useful information for breast carcinomas, since these two CLDN members are putative therapeutic targets. Comparing tumours with low expression of CLDN3, CLDN4 and CLDN7 with tumours previously referred to as CLDN-low by genomic assays, we demonstrated that the single IHC evaluation of these three specific CLDNs is insufficient to identify the CLDN-low molecular subtype of breast tumours. The analysis of several other molecular markers, such as EMT (epithelial-to-mesenchymal transition) and CSC (cancer stem cell) markers should probably be added to improve the identification of this subgroup of tumours by IHC, which probably are enriched in carcinomas with metaplastic differentiatio

Clinicopathological significance of ERCC1 expression in breast cancer

The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy in different types of cancer. The aim of the present study was to evaluate the clinicopathological significance of ERCC1 expression in breast cancer patients. We analyzed the immunohistochemical expression of ERCC1 in a tissue microarray from 135 primary breast carcinomas and correlated the immunohistochemical findings with clinicopathological factors and outcome data. ERCC1 expression analysis was available for 109 cases. In this group, 58 (53.2%) were positive for ERCC1. ERCC1-positive expression was correlated with smaller tumor size (P=0.007) and with positivity for estrogen receptor (P=0.040), but no correlation was found with other clinicopathological features. Although not statistically significant, triple negative breast cancers were more frequently negative for ERCC1 (61.5% of the cases) compared to the non-triple negative breast cancer cases (41.5%). In conclusion, ERCC1 expression correlated significantly with favorable prognostic factors, such as smaller tumor size and ER-positivity, suggesting a possible role for ERCC1 as a predictive and/or prognostic marker in breast cancer. © 2013 Elsevier GmbH

Insights concerning partial verification bias in retrospective fnac studies

1195594595sem informaçãosem informaçã

High Diagnostic Accuracy And Reproducibility Of Fine-needle Aspiration Cytology For Diagnosing Salivary Gland Tumors: Cytohistologic Correlation In 182 Cases.

The purpose of this study was to assess the efficacy and reproducibility of the cytologic diagnosis of salivary gland tumors (SGTs) using fine-needle aspiration cytology (FNAC). The study aimed to determine diagnostic accuracy, sensitivity, and specificity and to evaluate the extent of interobserver agreement. We retrospectively evaluated SGTs from the files of the Division of Pathology at the Clinics Hospital of São Paulo and Piracicaba Dental School between 2000 and 2006. We performed cytohistologic correlation in 182 SGTs. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were 94%, 100%, 100%, 100%, and 99%, respectively. The interobserver cytologic reproducibility showed significant statistical concordance (P < .0001). FNAC is an effective tool for performing a reliable preoperative diagnosis in SGTs and shows high diagnostic accuracy and consistent interobserver reproducibility. Further FNAC studies analyzing large samples of malignant SGTs and reactive salivary lesions are needed to confirm their accuracy.118226-3